We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.
- Authors
Mouraviev, Vladimir; Mariados, Neil; Albala, David; Concepcion, Raoul S.; Shore, Neal D.; Sims, Robert B.; Emberton, Mark; Pieczonka, Christopher M.
- Abstract
Immunotherapy encourages the recipient's own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first therapeutic cancer vaccine to be approved by both the US Food and Drug Administration and European Medicines Agency for the treatment of asymptomatic or minimally symptomatic mCRPC. Combining immunotherapy with other treatments may have potent anticancer effects; cytoreductive therapies can release tumor antigens and promote a proinflammatory environment that could augment immunotherapies. However, some cytoreductive agents or coadministered drugs may be immunosuppressive. Understanding these interactions between different mCRPC treatment modalities may offer further potential to improve patient outcomes.
- Subjects
SIPULEUCEL-T (Drug); CASTRATION; PROSTATE cancer; IMMUNOTHERAPY; IMMUNE response; CANCER cells; CANCER chemotherapy; IMMUNOSUPPRESSIVE agents
- Publication
Reviews in Urology, 2014, Vol 16, Issue 3, p122
- ISSN
1523-6161
- Publication type
Article
- DOI
10.3909/riu0637